VAT gewinnt den Supplier Excellence Award 2019 von LAM Research
» Report
Einige Inhalte dieser Seite sind nur für Abonnenten sichtbar.
Anmelden oder
Jetzt abonnieren!
Archiv: Alle Kategorien
ABB begins construction of new robotics factory in Shanghai
» Report
World Gold Council: World Gold Council führt Grundsätze für einen verantwortungsbewussten Goldabbau ein
» World Gold Council
Peach Property: Kauf von über 3.650 Wohnungen in Deutschland – Wert des Bestandsportfolios steigt auf rd. CHF 1,1 Mrd
» Peach Property
Roche’s satralizumab significantly reduced relapse risk in second positive phase III study for neuromyelitis optica spectrum
» Report
GROUPE ROMANDE ENERGIE
» Report
Dufry signs new contract and expands its operations; in Florianópolis International Airport
» Report
Newron reports half-year 2019 results
» Report
Roche’s Tecentriq as a first-line monotherapy helped certain people with advanced non-small cell lung cancer live longer compared with chemotherapy
» Report
The transHuman Code Bestseller and Ethics in AI Debated at the 2019 Zermatt Summit
» Report
Newron berichtet über das Halbjahresergebnis 2019
» Report
dormakaba 2018/19 financial results: Further increase in profitability, higher dividend proposed again
» Report
dormakaba Geschäftsergebnisse 2018/19: Weitere Steigerung der Profitabilität, erneut höhere Dividende beantragt
» Report
SGS Launches New Service for International Type Approval (ITA) Restricted Substance Compliance
» Report
ObsEva announces new composition of its Executive Committee
» Report
Flughafen Zürich: Verkehrsstatistik vom August 2019
» Report
Key traffic figures Zurich Airport August 2019 In August
» Report
Kudelski Security named a Major Player in the IDC MarketScape: U.S. Emerging Managed Security Services
» Report
Idorsia Ltd: Janssen reports new head-to-head Phase 3 study data show ponesimod superiority versus Aubagio (teriflunomide) 14 mg in adults with relapsing multiple sclerosis
» Report
Idorsia Ltd: Janssen reports new head-to-head Phase 3 study data show ponesimod superiority versus Aubagio (teriflunomide) 14 mg in adults with relapsing multiple sclerosis
» Report
